Core Viewpoint - The article discusses the promising results of Mazdutide, a dual agonist of GLP-1 and GCG receptors, in weight management and its potential impact on obesity treatment guidelines globally [2][3]. Group 1: Drug Mechanism and Development - Mazdutide activates GLP-1 receptors to suppress appetite and delay gastric emptying, while also activating GCG receptors to promote liver fat breakdown and enhance energy expenditure, addressing both weight loss and fatty liver issues [2]. - The clinical trial results of Mazdutide were published in the prestigious New England Journal of Medicine, marking a significant milestone for Chinese drug development in the field of metabolic and endocrine diseases [3][6]. Group 2: Clinical Trial Results - In a Phase 3, double-blind, placebo-controlled trial involving 610 participants, the average weight loss at 32 weeks for the 6 mg group was 12.55% (approximately 11 kg), and at 48 weeks, it was 14.01% (approximately 12 kg) [6][9]. - The trial showed that 49.5% of participants in the 6 mg group lost over 15% of their body weight, indicating significant efficacy in weight management [9]. Group 3: Safety and Side Effects - The most commonly reported adverse events were gastrointestinal-related, primarily mild to moderate, with a low incidence of treatment discontinuation due to side effects: 0.5% in the 6 mg group compared to higher rates in similar drugs [8][9]. - The study confirmed the high safety profile of Mazdutide, with side effects concentrated in the initial treatment phase [8].
中国原创减肥药登上NEJM：效果媲美司美格鲁肽，且因副作用而停药的概率更低